Vistagen reports preliminary open-label data from PALISADE-4 extension for fasedienol
The company said as-needed use of the nasal spray for up to a year showed no new safety concerns and improvement on anxiety scales over four months.
SEC filing
Latest
4 stories
Tuesday, September 22
Friday, August 14
Vistagen plans FDA meeting on fasedienol path after mixed PALISADE-4 data
Vistagen reported fiscal Q1 2027 results and said it plans to meet with the FDA this quarter to discuss a possible Phase 3 path for fasedienol in social anxiety disorder.
SEC filing
Thursday, August 6
Vistagen reports Phase 2 repeat dose results for fasedienol in social anxiety disorder
The exploratory trial was not designed to reach statistical significance, but showed a nominally significant effect in patients with very severe social anxiety.
SEC filing
Friday, July 31
Vistagen adds Douglas J. Williamson to board of directors
The neuroscience drug development veteran joins as Vistagen advances its pherine pipeline, including Phase 3 fasedienol for social anxiety disorder.
SEC filing